Our results suggest that elevation of brain PIP2 through reduction of synj1 expression could be a potential therapeutic strategy to prevent the development of neurodegeneration after TBI, and to possibly improve clinical outcomes of those affected by TBI-AD particularly in ApoE4 carriers. Here, APOE is linked to Alzheimer disease.